Pharmacia Diagnostics, Device Operations Are Outside Pfizer Drug Focus
This article was originally published in The Gray Sheet
Executive Summary
Pfizer's strategy to exit the medical device business in the late 1990s to focus on its core pharmaceutical business portends a similar fate for Pharmacia's device and diagnostics operations following the completion of the companies' $60 bil. consolidation
You may also be interested in...
Howmedica Is Sole Remaining Pfizer Device Business Following AMS Sale
Pfizer's proposed $130 mil. sale of its American Medical Systems urological products business to the investment firm of E.M. Warburg, Pincus & Co., announced July 22, leaves the Howmedica orthopedics business the sole remaining unit of the Pfizer medical technology group.
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.